The G11 molecule targets cells that develop a mutation in the FLT3 receptor, which is important for cell propagation and proliferation. The mutant is most common in acute myeloid leukaemia 1 ...
Gene mutations in acute myeloid leukemia (AML) cells can guide treatment options, and machine learning can rapidly guess the ...
Three years after Daiichi Sankyo's FLT3 inhibitor quizartinib was rejected by the FDA, the drugmaker has reported the results of a new phase 3 trial that is key to getting the drug to the US ...
Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT ... KIT, and FLT3 inhibitor that was cleared for TGCT by the FDA in ...
Tenosynovial giant cell tumor, also known as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath ...
Moreover, this combination is active against P53-negative and FLT3-ITD-positive cell lines. Enhanced activation of apoptosis was observed in leukemia patient-derived cell samples exposed to the ...
It becomes the second US Food and Drug Administration-approved drug for the disease after Daiichi Sankyo's Turalio (pexidartinib), a CSF1R, KIT, and FLT3 inhibitor that was cleared by the US Food and ...
Sorafenib is an oral tyrosine kinase inhibitor able to inhibit VEGF receptors 1, 2 and 3, PDGF receptors α and β, RET, Flt3, c-KIT and ... of advanced renal cell carcinoma and unresectable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback